These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15163266)

  • 41. Augmentation of clozapine with valproic Acid for clozapine-induced obsessive-compulsive symptoms.
    Zink M; Englisch S; Knopf U; Kuwilsky A; Dressing H
    Pharmacopsychiatry; 2007 Sep; 40(5):202-3. PubMed ID: 17874353
    [No Abstract]   [Full Text] [Related]  

  • 42. Pipamperone augmentation of clozapine and sodium valproate in refractory schizophrenia: a case report.
    Paraschakis A
    Clin Neuropharmacol; 2014; 37(2):60-1. PubMed ID: 24614672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients.
    Cutler NR
    J Clin Psychiatry; 2001; 62 Suppl 5():10-3; discussion 23-4. PubMed ID: 11305842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New developments in the pharmacological treatment of schizophrenia.
    Kane JM
    Bull Menninger Clin; 1992; 56(1):62-75. PubMed ID: 1348197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clozapine levels might be affected by excessive cola consumption.
    Al Hadithy A; Leeffers E; Bruggeman R
    J Clin Psychopharmacol; 2012 Oct; 32(5):717-9. PubMed ID: 22926611
    [No Abstract]   [Full Text] [Related]  

  • 46. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients.
    Trichard C; Paillère-Martinot ML; Attar-Levy D; Recassens C; Monnet F; Martinot JL
    Am J Psychiatry; 1998 Apr; 155(4):505-8. PubMed ID: 9545996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Branded versus generic clozapine for treatment of schizophrenia.
    Makela EH; Cutlip WD; Stevenson JM; Weimer JM; Abdallah ES; Akhtar RS; Aboraya AS; Gunel E
    Ann Pharmacother; 2003 Mar; 37(3):350-3. PubMed ID: 12639161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Twice-daily dosing of valproate with divalproex.
    Wilder BJ; Karas BJ; Hammond EJ; Perchalski RJ
    Clin Pharmacol Ther; 1983 Oct; 34(4):501-4. PubMed ID: 6413118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population pharmacokinetic/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia.
    Shang DW; Li LJ; Wang XP; Wen YG; Ren YP; Guo W; Li WB; Li L; Zhou TY; Lu W; Wang CY
    Ther Drug Monit; 2014 Jun; 36(3):378-86. PubMed ID: 24342896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia.
    Kelly DL; Conley RR; Feldman S; Yu Y; McMahon RP; Richardson CM
    Psychiatr Q; 2006; 77(1):81-95. PubMed ID: 16397757
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment-refractory schizophrenia in children and adolescents: an update on clozapine and other pharmacologic interventions.
    Kranzler HN; Kester HM; Gerbino-Rosen G; Henderson IN; Youngerman J; Beauzile G; Ditkowsky K; Kumra S
    Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):135-59. PubMed ID: 16321728
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
    Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
    J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients.
    Wong JO; Leung SP; Mak T; Ng RM; Chan KT; Hon-Kee Cheung H; Choi WK; Lai J; Wai-Kiu Tsang A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):251-64. PubMed ID: 16316716
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antipsychotic medication in the treatment of schizophrenia.
    Kane JM
    Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potential impact of valproic acid therapy on clozapine disposition.
    Finley P; Warner D
    Biol Psychiatry; 1994 Oct; 36(7):487-8. PubMed ID: 7811848
    [No Abstract]   [Full Text] [Related]  

  • 56. Worsening of psychotic symptoms in schizophrenia with addition of lamotrigine: a case report.
    Chan YC; Miller KM; Shaheen N; Votolato NA; Hankins MB
    Schizophr Res; 2005 Oct; 78(2-3):343-5. PubMed ID: 16085390
    [No Abstract]   [Full Text] [Related]  

  • 57. Valproic acid treatment of clozapine-induced myoclonus.
    Meltzer HY; Ranjan R
    Am J Psychiatry; 1994 Aug; 151(8):1246-7. PubMed ID: 8080553
    [No Abstract]   [Full Text] [Related]  

  • 58. A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate.
    Bressolle F; Gomeni R; Alric R; Royer-Morrot MJ; Necciari J
    J Pharm Sci; 1994 Oct; 83(10):1461-4. PubMed ID: 7884670
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response.
    Nyberg S; Nakashima Y; Nordström AL; Halldin C; Farde L
    Br J Psychiatry Suppl; 1996 May; (29):40-4. PubMed ID: 8733822
    [No Abstract]   [Full Text] [Related]  

  • 60. Clozapine conflict.
    Carpenter WT; Conley RR; Buchanan RW; Breier A; Tamminga CA
    Am J Psychiatry; 1996 Nov; 153(11):1505-7. PubMed ID: 8890695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.